Loss of Microbiota-Mediated Colonization Resistance to Clostridium difficile Infection With Oral Vancomycin Compared With Metronidazole.
暂无分享,去创建一个
Nora C. Toussaint | C. Buffie | E. Pamer | Asia Gobourne | Lilan Ling | Ingrid M Leiner | Brittany B Lewis | Charlie G Buffie | Rebecca A Carter | Ingrid Leiner | Nora C Toussaint | Liza C Miller | Asia Gobourne | Lilan Ling | Eric G Pamer | Liza Miller | R. Carter | Brittany B. Lewis
[1] C. Bassis,et al. Alteration of the Murine Gastrointestinal Microbiota by Tigecycline Leads to Increased Susceptibility to Clostridium difficile Infection , 2014, Antimicrobial Agents and Chemotherapy.
[2] C. Donskey,et al. Appropriateness of empiric therapy in patients with suspected Clostridium difficile infection , 2013, Current medical research and opinion.
[3] Stuart Johnson,et al. An epidemic, toxin gene-variant strain of Clostridium difficile. , 2005, The New England journal of medicine.
[4] Melinda B Davis,et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] Jeffrey D Goldsmith,et al. A mouse model of Clostridium difficile-associated disease. , 2008, Gastroenterology.
[6] R. Knight,et al. UniFrac: a New Phylogenetic Method for Comparing Microbial Communities , 2005, Applied and Environmental Microbiology.
[7] R. Owens,et al. Clostridium difficile–Associated Disease: An Emerging Threat to Patient Safety: Insights from the Society of Infectious Diseases Pharmacists , 2006, Pharmacotherapy.
[8] Martin Hartmann,et al. Introducing mothur: Open-Source, Platform-Independent, Community-Supported Software for Describing and Comparing Microbial Communities , 2009, Applied and Environmental Microbiology.
[9] T. Peto,et al. Whole-Genome Sequencing Demonstrates That Fidaxomicin Is Superior to Vancomycin for Preventing Reinfection and Relapse of Infection With Clostridium difficile , 2013, The Journal of infectious diseases.
[10] Louis Valiquette,et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity , 2004, Canadian Medical Association Journal.
[11] D. Musher,et al. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. , 2005, The Lancet. Infectious diseases.
[12] L. Valiquette,et al. Vancomycin or Metronidazole for Treatment of Clostridium difficile Infection: Clinical and Economic Analyses , 2011 .
[13] Chris Sander,et al. Precision microbiome restoration of bile acid-mediated resistance to Clostridium difficile , 2014, Nature.
[14] R. Guerrant,et al. Vancomycin Treatment's Association with Delayed Intestinal Tissue Injury, Clostridial Overgrowth, and Recurrence of Clostridium difficile Infection in Mice , 2012, Antimicrobial Agents and Chemotherapy.
[15] T. Riley,et al. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. , 2014, The Journal of antimicrobial chemotherapy.
[16] L. Brandt,et al. The Evolution of Urban C. difficile Infection (CDI): CDI in 2009–2011 Is Less Severe and has Better Outcomes Than CDI in 2006–2008 , 2014, The American Journal of Gastroenterology.
[17] J. Bartlett,et al. Historical perspectives on studies of Clostridium difficile and C. difficile infection. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] A. Viale,et al. Profound Alterations of Intestinal Microbiota following a Single Dose of Clindamycin Results in Sustained Susceptibility to Clostridium difficile-Induced Colitis , 2011, Infection and Immunity.
[19] N. Socci,et al. Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. , 2010, The Journal of clinical investigation.
[20] K. Garey,et al. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. , 2008, The Journal of hospital infection.
[21] M. Pirmohamed,et al. Emergence and global spread of epidemic healthcare-associated Clostridium difficile , 2012, Nature Genetics.
[22] A. Viale,et al. Familial transmission rather than defective innate immunity shapes the distinct intestinal microbiota of TLR-deficient mice , 2012, The Journal of experimental medicine.
[23] T. Louie,et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[24] Pamela Sears,et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. , 2011, The New England journal of medicine.
[25] C. Donskey,et al. Defining the Vulnerable Period for Re-Establishment of Clostridium difficile Colonization after Treatment of C. difficile Infection with Oral Vancomycin or Metronidazole , 2013, PloS one.
[26] N. Khardori. Clostridium difficile infection in Europe: a hospital-based survey , 2011 .
[27] James A. Foster,et al. Phylogenetics Clearcut : a fast implementation of relaxed neighbor joining , 2006 .
[28] S. Rodríguez,et al. Risk of Clostridium difficile infection in hospitalized patients receiving metronidazole for a non-C difficile infection. , 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[29] T. Wilt,et al. Comparative Effectiveness of Clostridium difficile Treatments , 2011, Annals of Internal Medicine.
[30] Eoin L. Brodie,et al. Greengenes, a Chimera-Checked 16S rRNA Gene Database and Workbench Compatible with ARB , 2006, Applied and Environmental Microbiology.
[31] Marti J. Anderson,et al. A new method for non-parametric multivariate analysis of variance in ecology , 2001 .